Dr. Renato G. Martins on Nivolumab and its Role as a Second-Line Treatment in NSCLC
​Renato G. Martins, MD, MPH, discusses why nivolumab is not ready to move up to being a firstline treatment in non
Renato G. Martins, MD, MPH, Medical Director, Thoracic/Head and Neck Medical Oncology, Seattle Cancer Care Alliance, discusses nivolumab in nonsmall cell lung cancer (NSCLC). Martins says while there are a number of trials where nivolumab is being combined with chemotherapy to increase its efficacy, the treatment is not ready for the firstline. He says until there is a reliable biomarker to identify which patients would benefit from the treatment, it would be difficult to move nivolumab into the frontline.
Articles in this issue
Dr. Renato G. Martins on Nivolumab and its Role as a Second-Line Treatment in NSCLC
Dr. Geoffrey R. Oxnard Treating EGFR-Inhibitor Resistant Patients With Lung Cancer
Marianne Davies, NP, on Assessing Immunotherapy Toxicities in Lung Cancer Patients
Research Team Challenges Plant-Derived Molecule for the Treatment of NSCLC
Combining Immunotherapy With Anti-VEGF Agents Rigorously Explored in NSCLC
Lung Cancer Research Shows Distinct Genomic Differences in Younger Patients
Lung Cancer Incidence and Mortality Review Shows No Ethnic Differences in Women
NSCLC Study Shows Surprising Association Between Reduced Endocytic Activity and Metastases
Related Videos
